Piper Sandler reiterated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report released on Thursday, TipRanks reports. Piper Sandler currently has a $104.00 target price on the stock.
Several other research analysts have also commented on CRSP. Canaccord Genuity lifted their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research report on Wednesday, November 20th. ValuEngine lowered Crispr Therapeutics from a hold rating to a sell rating in a research report on Friday, January 3rd. Chardan Capital reiterated a buy rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research report on Thursday. BidaskClub lowered Crispr Therapeutics from a sell rating to a strong sell rating in a research report on Tuesday, February 11th. Finally, Piper Jaffray Companies reiterated a buy rating and issued a $104.00 target price on shares of Crispr Therapeutics in a research report on Monday, December 16th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Crispr Therapeutics currently has a consensus rating of Buy and an average price target of $78.29.
Shares of NASDAQ CRSP opened at $55.80 on Thursday. Crispr Therapeutics has a fifty-two week low of $30.75 and a fifty-two week high of $74.00. The business has a 50 day moving average price of $57.63 and a two-hundred day moving average price of $53.03. The firm has a market cap of $3.40 billion, a PE ratio of 57.53 and a beta of 3.26.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $1.19. Crispr Therapeutics had a return on equity of 11.74% and a net margin of 23.09%. The firm had revenue of $77.00 million during the quarter, compared to analyst estimates of $39.08 million. During the same quarter last year, the firm earned ($0.92) EPS. Crispr Therapeutics’s quarterly revenue was up 76900.0% on a year-over-year basis. As a group, equities analysts anticipate that Crispr Therapeutics will post -4.61 EPS for the current year.
In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. 21.40% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in CRSP. ARK Investment Management LLC raised its stake in Crispr Therapeutics by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock valued at $180,074,000 after acquiring an additional 174,495 shares in the last quarter. Farmers & Merchants Trust Co of Chambersburg PA bought a new stake in Crispr Therapeutics during the 4th quarter valued at $26,000. State Street Corp raised its stake in Crispr Therapeutics by 2.1% during the 3rd quarter. State Street Corp now owns 37,103 shares of the company’s stock valued at $1,521,000 after acquiring an additional 758 shares in the last quarter. Capital Advisors Inc. OK raised its stake in Crispr Therapeutics by 9.4% during the 4th quarter. Capital Advisors Inc. OK now owns 127,029 shares of the company’s stock valued at $7,737,000 after acquiring an additional 10,872 shares in the last quarter. Finally, Webster Bank N. A. bought a new stake in Crispr Therapeutics during the 4th quarter valued at $26,000. Institutional investors and hedge funds own 51.28% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.